Equities

Psyence Biomedical Ltd

PBM:NMQ

Psyence Biomedical Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.5898
  • Today's Change-0.030 / -4.78%
  • Shares traded556.36k
  • 1 Year change-94.64%
  • Beta--
Data delayed at least 15 minutes, as of Jul 30 2024 20:59 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Psyence Biomedical Ltd is a Canada-based company, which develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The Company has partnered with iNGENu Pty Ltd (iNGENu) to conduct the Company’s clinical trial in palliative care. iNGENu is an Australia-based, globally focused contract research organization (CRO) with experience working in the psychedelic pharmaceutical drug development and clinical research industry. Its Phase IIb clinical trial, using PEX010, a 25mg naturally derived psilocybin drug candidate product in-licensed by the Company, in the palliative care setting.

  • Revenue in USD (TTM)0.00
  • Net income in USD1.52m
  • Incorporated2023
  • Employees--
  • Location
    Psyence Biomedical Ltd121 Richmond Street West PenthouseSuite 1300TORONTO M5H 2K1CanadaCAN
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Sonoma Pharmaceuticals Inc12.74m-4.84m5.82m172.00--0.7782--0.4566-0.7237-0.72371.400.39320.82242.874.6674,040.70-31.22-29.36-41.09-40.6537.2638.00-37.97-30.932.64--0.05---4.05-7.666.13---29.84--
GT Biopharma Inc0.00-9.64m5.91m2.00--0.7123-----7.04-7.040.003.850.00----0.00-64.24-205.36-90.39--------------0.00------63.62------
Integrated BioPharma, Inc.50.57m-116.00k6.02m141.00--0.318328.400.119-0.0041-0.00411.670.62831.884.4510.76358,617.00-0.43115.51-0.569827.947.0912.09-0.22946.441.02-9.000.001---9.913.00-101.35---14.03--
Sentient Brands Holdings Inc0.00-818.63k6.10m2.00---------0.0145-0.01450.00-0.0360.000.0188--0.00-317.87-220.36------41.81---31,451.190.0354-2.27-----73.68--34.98------
Biofrontera Inc33.25m-23.09m6.26m85.00------0.1883-12.47-12.4716.84-0.36270.99952.505.75391,200.00-69.40---144.06--48.99---69.44--0.944-3.554.63--18.82---3,045.47------
Shuttle Pharmaceuticals Holdings Inc0.00-7.35m6.72m8.00--2.44-----0.4739-0.47390.000.16420.00----0.00-96.75---119.37-------------5.280.2542-------112.71------
Sunshine Biopharma Inc26.74m-4.09m6.89m44.00--0.0118--0.2577-13.35-13.3576.9624.960.90813.1311.58607,722.50-13.88-101.52-17.99-137.0433.1535.47-15.29-165.333.23--0.00--454.42--83.15--110.99--
Cannapharmarx Inc25.84k-6.61m7.29m21.00------282.02-0.0205-0.02050.00008-0.04250.0031--0.45031,230.48-79.52-131.06-----1,692.76---25,598.30--0.0033-0.1306--------143.24------
Vestiage Inc0.00-21.76k7.70m0.00---------0.0004-0.00040.00-0.00110.00-------4,945.46---------------------------102.30------
Lotus Pharmaceuticals Inc70.79m1.72m8.08m233.000.05420.00082.090.11420.05530.05532.563.580.632137.2717.85303,836.901.5522.841.7126.4035.1041.622.4519.930.442830.800.05160.0028.7131.70-12.2251.1170.48--
Bon Natural Life Ltd29.52m4.60m8.09m96.000.40820.06741.470.2744.994.9932.1030.230.704515.275.19307,524.6010.8614.0413.6920.6829.9430.0015.4217.622.4130.540.09550.00-1.2922.32-26.3283.09-6.70--
CV Sciences Inc15.86m-3.23m8.18m42.00--3.46--0.5157-0.0207-0.02070.10120.01451.591.4227.25377,571.40-32.43-43.42-83.71-77.7545.1351.81-20.38-45.680.2677-13.320.0472---1.24-19.80133.96-20.87----
Psyence Biomedical Ltd0.001.52m8.29m------5.47---0.0442-0.04420.00-0.39790.00------1.13--1.20-----------------------2.63------
DH Enchantment Inc680.00-156.15k8.31m1.00------12,225.15-0.0002-0.00020.00-0.00120.07150.943745.33680.00-1,641.09-------60.29---22,963.23--0.0032-13.28-----95.43--59.53------
Coeptis Therapeutics Holdings Inc0.00-16.31m9.54m5.00--2.15-----0.5804-0.58040.000.11970.00----0.00-212.70-36.90-378.58-37.81------------0.349------43.40------
Tonix Pharmaceuticals Holding Corp10.25m-98.59m9.88m103.00--0.0121--0.9638-177.41-177.419.4646.940.0652----99,514.56-62.71-59.46-70.20-65.9237.55---961.87-5,126.730.8666--0.0767------0.1874--320.57--
Data as of Jul 30 2024. Currency figures normalised to Psyence Biomedical Ltd's reporting currency: US Dollar USD

Institutional shareholders

15.24%Per cent of shares held by top holders
HolderShares% Held
Harraden Circle Investments LLCas of 25 Jan 20241.30m9.71%
Cantor Fitzgerald & Co.as of 31 Mar 2024337.00k2.52%
AdvisorShares Investments LLCas of 31 Mar 2024271.34k2.03%
Two Sigma Securities LLCas of 31 Mar 202455.78k0.42%
Virtu Americas LLCas of 31 Mar 202426.42k0.20%
TD Securities (USA) LLCas of 31 Mar 202425.00k0.19%
HRT Financial LLCas of 31 Mar 202412.61k0.09%
Geode Capital Management LLCas of 31 Mar 202410.49k0.08%
UBS Securities LLCas of 31 Mar 20242.36k0.02%
Headlands Technologies LLCas of 31 Mar 202496.000.00%
More ▼
Data from 31 Mar 2024 - 10 Jul 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.